These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7833113)

  • 1. p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases.
    Domagala W; Striker G; Szadowska A; Dukowicz A; Harezga B; Osborn M
    Eur J Cancer; 1994; 30A(10):1527-34. PubMed ID: 7833113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
    Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
    Kourea HP; Koutras AK; Scopa CD; Marangos MN; Tzoracoeleftherakis E; Koukouras D; Kalofonos HP
    Mol Pathol; 2003 Dec; 56(6):328-35. PubMed ID: 14645695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.
    MacGrogan G; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
    Breast Cancer Res Treat; 1995; 36(1):71-81. PubMed ID: 7579509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
    Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.
    Domagala W; Markiewski M; Kubiak R; Bartkowiak J; Osborn M
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(6):497-502. PubMed ID: 8291222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer.
    Wang W; Tang M; Zhang L; Xu X; Qi X; Yang Y; Jin F; Chen B
    Jpn J Clin Oncol; 2013 Dec; 43(12):1170-6. PubMed ID: 24106298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.
    Heatley MK; Ewings P; Odling Smee W; Maxwell P; Toner PG
    Pathology; 2002 Jun; 34(3):230-2. PubMed ID: 12109782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.
    Xiao J; Zhou Y; Zhu W
    Int J Clin Exp Pathol; 2015; 8(6):6458-65. PubMed ID: 26261522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
    Domagala W; Striker G; Szadowska A; Dukowicz A; Weber K; Osborn M
    Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship.
    Purushotham A; Shamil E; Cariati M; Agbaje O; Muhidin A; Gillett C; Mera A; Sivanadiyan K; Harries M; Sullivan R; Pinder SE; Garmo H; Holmberg L
    Eur J Cancer; 2014 Jul; 50(10):1697-1705. PubMed ID: 24768572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A; Manoharan V
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.
    Domagala W; Lasota J; Dukowicz A; Markiewski M; Striker G; Weber K; Osborn M
    Am J Pathol; 1990 Dec; 137(6):1299-304. PubMed ID: 1701960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male breast cancer--a reappraisal of clinical and biologic indicators of prognosis.
    André S; Fonseca I; Pinto AE; Cardoso P; Pereira T; Soares J
    Acta Oncol; 2001; 40(4):472-8. PubMed ID: 11504306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
    Gursan N; Karakök M; Sari I; Gursan MS
    Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
    Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
    J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
    Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
    Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.